The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | How can adherence to treatment protocols for resectable NSCLC be improved?
Francesco Guerrera, MD, University of Turin, Turin, Italy, comments on treatment adherence to neoadjuvant immunotherapy with or without standard chemotherapy. Real-life adherence rates may be lower than in clinical trial settings, and patients may not undergo surgery after treatment due to disease progression or toxicity. Changes in current protocols might further improve adherence results. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
